# Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

> **NCT05125679** · PHASE4 · TERMINATED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Guselkumab

## Key facts

- **NCT ID:** NCT05125679
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-23
- **Primary completion:** 2023-07-28
- **Final completion:** 2023-07-28
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Terminated (A strategic decision was made not to further execute the study. This decision was not based on a safety concern)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05125679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05125679, "Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05125679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*